A compound for targeted degradation of Polθ and its preparation method and use
By developing compounds that target the degradation of Polθ, a multi-step synthesis technology is used to form Polθ proteins that can significantly degrade Polθ at low doses, solving the problem of difficulty in effectively degrading Polθ in the prior art, and it has application potential in cancer treatment.
Patent Information
- Application Number
- CN202410977562.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-22
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-07-22
AI Technical Summary
The prior art is difficult to effectively degrade DNA polymerase θ (Polθ) protein at low doses. Polθ is up-regulated in various cancers and is related to cancer prognosis. Cells lacking DNA repair pathways are highly dependent on their activity. Current targeted treatments The method is not sufficient to effectively degrade the protein.
A compound targeting the degradation of Polθ has been developed, whose structure includes a combination of specific Linker and D parts, synthesized by Suzuki reaction, substitution reaction and condensation reaction to form a compound capable of significantly degrading Polθ at low doses.
Significantly degrading Polθ protein at low doses has the potential for application in the treatment and prevention of cancer. Specific embodiments include multi-step synthesis processes and structural optimization of compounds to achieve effective inhibition of Polθ.
Smart Images

Figure CN118515661B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a compound for targeted degradation of Polθ and a preparation method and application thereof, belonging to the field of medicinal chemistry. Background Art
[0002] Synthetic lethality provides a new approach for the treatment of mutant genes that were previously considered untargetable in traditional genotype-targeted therapies. DNA polymerase θ (Polθ, encoded by the POLQ gene) plays an important role in the microhomology end-mediated repair pathway. Polθ consists of a C-terminal DNA polymerase domain, an N-terminal ATPase / helicase domain, and a disordered central domain. In homologous recombination-deficient cells, Polθ can perform error-prone DNA synthesis at DNA damage sites through the microhomology end-mediated repair pathway and is synthetically lethal to homologous recombination (HR)-deficient cancers. Polθ is largely unexpressed in normal cells, but is upregulated in a variety of cancers, including breast cancer, lung cancer, colorectal cancer, ovarian cancer, and gastric cancer. In addition, increased Polθ expression is associated with a poor prognosis in breast cancer. The survival of cancer cells lacking HR, NHEJ, or ATM is highly dependent on the activity of Polθ. Therefore, Polθ is an attractive target for novel synthetic lethal therapies in cancers with DNA repair defects. Summary of the invention
[0003] Purpose of the invention: The technical problem to be solved by the present invention is to provide a compound for targeted degradation of Polθ and its preparation method and use, which can significantly degrade Polθ protein at a low dose.
[0004] Technical solution: To solve the above technical problems, the present invention provides a compound for targeted degradation of Polθ or a pharmaceutically acceptable salt thereof, wherein the structural formula of the compound for targeted degradation of Polθ is shown in general formula (I):
[0005] ;
[0006] (I)
[0007] in,
[0008] Linker is selected from a saturated alkyl group with 3 to 10 carbon atoms or an alkoxy group with 4 to 6 carbon atoms;
[0009] D is selected from:
[0010] .
[0011] Wherein, the linker is selected from a saturated alkyl group having 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms.
[0012] Wherein, the linker is selected from an alkoxy group having 4, 5, or 6 carbon atoms.
[0013] Wherein, the Linker is selected from any one of the following structures:
[0014] .
[0015] The present invention also provides a compound for targeted degradation of Polθ or a pharmaceutically acceptable salt thereof, wherein the structural formula of the compound for targeted degradation of Polθ is shown in any one of the following:
[0016] .
[0017] The present invention also provides a method for preparing the compound targeted for degradation of Polθ, comprising the following steps:
[0018] (1) (2-methoxyphenyl)boronic acid (compound 1) and 3-bromoisonicotinic acid methyl ester (compound 2) are reacted by Suzuki reaction to prepare 3-(2-methoxyphenyl)isonicotinic acid methyl ester (compound 3);
[0019] (2) Compound 3 is hydrolyzed under alkaline conditions to obtain 3-(2-methoxyphenyl)isonicotinic acid (compound 4);
[0020] (3) 5-bromo-1,3,4-thiadiazol-2-amine (compound 5) and methyl 4-hydroxymethylbenzoate (compound 6) are reacted to obtain methyl 4-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)benzoate (compound 7);
[0021] (4) Compounds 4 and 7 react with the condensing agent 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) to produce methyl 4-(((5-(3-(2-methoxyphenyl)isonicotinamido)-1,3,4-thiadiazol-2-yl)oxy)methyl)benzoate (compound 8);
[0022] (5) Compound 8 is hydrolyzed under alkaline conditions to obtain 4-(((5-(3-(2-methoxyphenyl)isonicotinamido)-1,3,4-thiadiazol-2-yl)oxy)methyl)benzoic acid (Compound 9);
[0023] (6) The linker module is firstly deprotected from the Boc protecting group and then reacted with compound 9 to obtain the target compound of formula (I).
[0024] The present invention also provides the use of the compound targeted for degradation of Polθ or a pharmaceutically acceptable salt thereof in the preparation of a drug targeted for degradation of Polθ.
[0025] The present invention also provides the use of the compound targeted for degradation of Polθ or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating and / or preventing cancer.
[0026] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages: compared with the negative control group, the compounds in the present invention can significantly degrade Polθ protein at a low dose. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 This is the degradation effect of some compounds on Polθ protein in MDA-MB-436 cells. DETAILED DESCRIPTION
[0028] The technical solution of the present invention is further described below in conjunction with the accompanying drawings.
[0029] The NMR spectra of the final products and intermediates in the examples are based on DMSO- d 6 or CDCl3- d 3 The samples were measured by a 300 MHz or 400 MHz NMR instrument from Bruker with TMS as the solvent and an Agilent Q-TOF 6520 mass spectrometer.
[0030] The reagents used in the synthesis, purification and separation of the compounds are as follows: (1) Column chromatography silica gel: 200 or 300 mesh silica gel was purchased from Qingdao Ocean Chemical Co., Ltd.; (2) HSGF254 TLC thin layer chromatography plate: purchased from Yantai Chemical Research Institute; (3) Conventional solvents used in column chromatography elution systems such as petroleum ether, dichloromethane, ethyl acetate, methanol, etc. and chemical reagents required for the reaction, unless otherwise specified, were all commercially available chemically pure or analytically pure products.
[0031] Example 1: Synthesis of Linker Derivatives 11a-11k
[0032] 2-(2,6-dioxopiperidin-3-yl)-4-fluoro-isoindoline-1,3-dione (D1, 0.28 g, 1.0 mmol) was dissolved in 5 ml of anhydrous DMF, and amine compounds 10a-10i (1.0 mmol) of different lengths and N,N-diisopropylethylamine (DIPEA, 0.4 g, 3.0 mmol) were added in sequence under nitrogen protection, and the mixture was reacted at 90°C overnight. After the reaction was completed by TLC, the reaction solution was poured into water, extracted with ethyl acetate, and the organic layer was washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated to obtain yellow solids 11a-11i, which were directly cast without purification.
[0033] Synthesis route:
[0034] .
[0035] The synthesis of 11j and 11k was based on the same method as that of 11a-11i, except that D1 was replaced with 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (D2) of equal molar mass, and Linker was replaced with 1-(azetidin-3-yl)piperazine (10j) or 3,9-diazaspiro[5.5]undecane (10k) of equal molar mass. Other conditions remained unchanged to obtain compounds 11i and 11k.
[0036] Synthesis route:
[0037] .
[0038] Example 2: Synthesis of N-(5-((4-((3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propyl)carbamoyl)benzyl)oxy)-1,3,4-thiadiazol-2-yl)-3-(2-methoxyphenyl)isonicotinamide (12a)
[0039] Structural formula:
[0040] Reference synthesis route:
[0041]
[0042] Step 1:
[0043] At room temperature, 2-methoxyphenylboronic acid (compound 1, 20.0 g, 131.63 mmol) and methyl 3-bromoisonicotinate (compound 2, 1.2 g, 131.63 mmol) were dissolved in 160 ml of 1,4-dioxane, and potassium carbonate (54.5 g, 394.87 mmol), 20 ml of water and 1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride (Pd(dppf)Cl2, 3.0 g, 0.03 mmol) were added in sequence, and the mixture was reacted at 80 °C overnight under nitrogen protection. TLC monitored the completion of the reaction. After the reaction was cooled to room temperature, water was added, extracted with ethyl acetate, washed with water, washed with saturated brine, dried over anhydrous Na2SO4, distilled under reduced pressure, and column chromatography was performed to obtain 20.0 g of a white solid (compound 3).
[0044] Step 2:
[0045] 3-(2-methoxyphenyl)isonicotinic acid methyl ester (compound 3, 20.0 g, 82.88 mmol) was dissolved in 200 mL of a mixed solution of methanol and water (methanol: water = 1:1, v / v), and NaOH (10.0 g, 248.65 mmol) was added. The reaction was carried out at 50°C for 3 h. The reaction was monitored by TCL. The reaction solution was concentrated until no fraction flowed out, and the pH was adjusted to 4-5 with 10% dilute hydrochloric acid. A white solid was precipitated, filtered, and dried at 50°C to obtain 17 g of a white solid (compound 4). It was directly cast without purification.
[0046] Step 3:
[0047] Dissolve 5-bromo-1,3,4-thiadiazole-2-amine (compound 5, 5.0 g, 27.8 mmol) and methyl 4-hydroxymethylbenzoate (compound 6, 4.62 g, 27.8 mmol) in 10 ml of N,N-dimethylformamide (DMF), add N,N-diisopropylethylamine (DIPEA, 10.84 g, 83.4 mmol), and keep at 60°C overnight under N2 protection. TLC monitors the completion of the reaction. Add water, extract with ethyl acetate, wash with water, wash with saturated brine, dry with anhydrous Na2SO4, distill under reduced pressure, and obtain 1.5 g of yellow solid (compound 7) by column chromatography.
[0048] Step 4:
[0049] 3-(2-methoxyphenyl)isonicotinic acid (compound 4, 1.6 g, 6.8 mmol) and methyl 4-(((5-amino-1,3,4-thiadiazol-2-yl)oxy)methyl)benzoate (compound 7, 1.5 g, 5.67 mmol) were dissolved in 10 ml DMF, and 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU, Anaiji Chemical, 2.6 g, 3.5 mmol) and DIPEA (2.2 g, 8.74 mmol) were added in sequence. Under N2 protection, the reaction was allowed to proceed overnight at room temperature. The reaction was monitored by TCL. Water was added, the mixture was extracted with ethyl acetate, washed with water, washed with saturated brine, dried over anhydrous Na2SO4, distilled under reduced pressure, and column chromatography was performed to obtain 1.2 g of a white solid (compound 8).
[0050] Step 5:
[0051] Methyl 4-(((5-(3-(2-methoxyphenyl)isonicotinamido)-1,3,4-thiadiazol-2-yl)oxy)methyl)benzoate (Compound 8, 1.2 g, 2.52 mmol) was dissolved in 20 mL of a mixed solution of methanol and water (methanol: water = 1:1, v / v), lithium hydroxide (LiOH, 181.33 mg, 7.56 mmol) was added, and the mixture was reacted at 50°C for 3 h. The reaction was monitored by TCL to be complete. The reaction solution was concentrated until no fraction flowed out, and the pH was adjusted to 4-5 with 10% dilute hydrochloric acid to precipitate a white solid, which was filtered and dried at 50°C to obtain 1.0 g of a white solid (Compound 9). The mixture was directly cast without purification.
[0052] Step 6:
[0053] At room temperature, the linker chain 11a (60 mg, 0.14 mmol) was dissolved in 1 mL of ethyl acetate, and 1 mL of 2.0 mol / L hydrochloric acid-ethyl acetate solution (Annaiji Chemical, W810184) was added. The reaction was allowed to react at room temperature for 2 h. After the reaction was completed by TLC monitoring, the reaction was concentrated under reduced pressure to obtain 60 mg of a yellow solid, which was used directly in the next step. 4-(((5-(3-(2-methoxyphenyl)isonicotinamido)-1,3,4-thiadiazol-2-yl)oxy)methyl)benzoic acid (Compound 9, 100 mg, 0.22 mmol) was dissolved in 3 ml of anhydrous DMF, and DIPEA (71 mg, 0.55 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 42.18 mg, 0.22 mmol), and 1-hydroxybenzotriazole (HOBT, 29.73 mg, 0.22 mmol) were added in turn under ice bath. The mixture was stirred at room temperature for 15 min under N2 protection, and the above crude product was added. The reaction was continued at room temperature overnight. After the reaction was completed under TCL monitoring, water was added, the mixture was extracted with ethyl acetate, washed with water, washed with saturated brine, dried over anhydrous Na2SO4, evaporated under reduced pressure, and column chromatography was performed to obtain 20 mg of a yellow solid (12a). 1 H NMR (300 MHz, CDCl3) δ 9.59 (s, 1H), 8.69 (d, J = 4.8 Hz,1H), 8.61 (s, 1H), 7.71– 7.74 (m, 2H), 7.61 (d , J = 5.0 Hz, 1H), 7.50 – 7.33(m, 4H), 7.19 – 7.22(m, 1H), 7.08 – 6.98 (m, 2H), 6.96 – 6.83 (m, 3H), 6.42( t, J = 5.9 Hz, 1H), 5.47 – 5.31 (m, 2H), 4.98 – 4.82 (m, 1H), 3.52 – 3.66 (m,5H), 3.38 – 3.41 (m, 2H), 2.70 – 2.81(m, 3H), 2.07 ( d, J = 8.1 Hz, 1H), 1.91–2.01(m, 2H).HRMS (ESI): m / z, calcd for C 39 H 34 N8NaO8S [M + Na] + , 797.2112;found, 797.2114.
[0054] Example 3: Synthesis of N-(5-(4-(2-(2-(2-(2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)carbamoyl)benzyl)oxy)-1,3,4-thiadiazol-2-yl)-3-(2-methoxyphenyl)isonicotinamide (12b)
[0055] Structural formula:
[0056] Referring to the synthesis method of Example 2, the linker was replaced with pentane-1,5-diamine (11b) of equal molar mass, and other conditions remained unchanged. 1 H NMR (400 MHz, CDCl3) δ 11.15 (s, 1H), 9.24 (s, 1H), 8.70 (d, J = 5.1Hz, 1H), 8.62 (s, 1H), 7.73 (d, J = 7.8 Hz, 2H), 7.61 (d, J = 5.0 Hz, 1H), 7.45(t, J = 8.1 Hz, 3H), 7.38 (t, J = 8.1 Hz, 1H), 7.22 (d, J = 7.5 Hz, 1H), 7.04 (q, J =7.5 Hz, 2H), 6.88 (t, J = 9.5 Hz, 2H), 6.49 (d, J = 6.0 Hz, 1H), 6.22 (d, J = 5.7Hz, 1H), 5.46 – 5.35 (m, 2H), 4.86 – 4.91 (m, 1H), 3.61 (s, 3H), 3.46 (q, J =7.2 Hz, 2H), 3.28 (q, J = 6.4 Hz, 2H), 2.84 – 2.70 (m, 2H), 2.16 – 2.07 (m,1H), 1.69 (dt, J = 16.6, 7.6 Hz, 5H), 1.52 (q, J = 7.6 Hz, 2H).HRMS (ESI): m / z,calcd for C 41 H 38 N8NaO8S [M + Na] +, 825.2426; found, 825.2418.
[0057] Example 4: Synthesis of N-(5-(4-(2-(2-(2-(2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)carbamoyl)benzyl)oxy)-1,3,4-thiadiazol-2-yl)-3-(2-methoxyphenyl)isonicotinamide (12c)
[0058] Structural formula:
[0059] Referring to the synthesis method of Example 2, the linker was replaced with 2,2'-oxybis(ethyl-1-amine) (11c) of equal molar mass, and other conditions remained unchanged. 1 H NMR (400 MHz, CDCl3) δ 11.08 (s, 1H), 8.79 (d, J = 5.1 Hz,1H), 8.71 (s, 1H), 7.79 (d, J = 7.9 Hz, 2H), 7.63 (d, J = 5.0 Hz, 1H), 7.48 (t, J =7.8 Hz, 1H), 7.40 (d, J = 7.9 Hz, 2H), 7.35 (td, J = 8.0, 1.7 Hz, 1H), 7.25 (d, J =6.3 Hz, 1H), 7.10 (dd, J = 20.1, 5.6 Hz, 2H), 7.00 (t, J = 7.5 Hz, 1H), 6.90 (d, J = 8.5 Hz, 1H), 6.85 (d, J = 8.3 Hz, 1H), 6.70 (t, J = 5.2 Hz, 1H), 5.36 – 5.22(m, 2H), 4.76 (dd, J = 12.2, 5.3 Hz, 1H), 3.79 – 3.61 (m, 6H), 3.55 (s, 3H), 3.45 (p, J= 5.1 Hz, 2H), 2.88 – 2.54 (m, 3H), 2.06 – 1.99 (m, 1H).HRMS (ESI):m / z, calcd for C 40 H 36 N8NaO9S[M + Na] + , 827.2218; found, 827.2214.
[0060] Example 5: Synthesis of N-(5-((4-((6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)carbamoyl)benzyl)oxy)-1,3,4-thiadiazol-2-yl)-3-(2-methoxyphenyl)isonicotinamide (12d)
[0061] Structural formula:
[0062] Referring to the synthesis method of Example 2, the linker was replaced with hexane-1,6-diamine (11d) of equal molar mass, and other conditions remained unchanged. 1 H NMR (300 MHz, CDCl3) δ 9.18 (d, J = 3.6 Hz, 1H), 8.65 (d, J = 5.0 Hz,1H), 8.59 (s, 1H), 7.74 (d, J = 8.2 Hz, 2H), 7.59 (d, J = 5.0 Hz, 1H), 7.51 –7.31 (m, 4H), 7.19 (dd, J = 7.5, 1.8 Hz, 1H), 7.08 – 6.97 (m, 2H), 6.92 – 6.79(m, 2H), 6.64 (t, J = 5.7 Hz, 1H), 6.21 (t, J = 5.6 Hz, 1H), 5.37 (s, 2H), 4.86(dd, J = 11.9, 5.4 Hz, 1H), 3.58 (s, 3H), 3.42 (dd, J = 14.5, 7.9 Hz, 2H), 3.24(q, J = 6.5 Hz, 2H), 2.94 – 2.64 (m, 3H), 2.14 – 2.04 (m, 1H), 1.62 (q, J= 8.0Hz, 4H), 1.42 (h, J = 5.5 Hz, 4H).HRMS (ESI): m / z, calcd for C 42 H 40 N8NaO8S [M +Na] + , 839.2582; found, 839.2578.
[0063] Example 6: Synthesis of N-(5-((4-((8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)carbamoyl)benzyl)oxy)-1,3,4-thiadiazol-2-yl)-3-(2-methoxyphenyl)isonicotinamide (12e)
[0064] Structural formula:
[0065] Referring to the synthesis method of Example 2, the linker was replaced with octane-1,8-diamine (11e) of equal molar mass, and other conditions remained unchanged. 1 H NMR (300 MHz, CDCl3) δ 8.73 – 8.69 (m, 2H), 8.29 (t, J = 4.8 Hz,1H), 7.92 (dd, J = 6.9, 1.2 Hz, 1H), 7.88 – 7.81 (m, 3H), 7.64 (dd, J = 7.6, 1.3Hz, 1H), 7.52 (dd, J = 7.9, 6.8 Hz, 1H), 7.42 – 7.39 (m, 2H), 7.35 (td, J = 7.6,1.3 Hz, 1H), 7.33 – 7.25 (m, 1H), 7.14 – 7.07 (m, 2H), 6.98 (dd, J = 7.6, 1.2Hz, 1H), 5.48 – 5.37 (m, 2H), 4.99 – 4.85 (m, 1H), 3.87 (s, 3H), 3.28 (dq, J =20.4, 5.4 Hz, 4H), 2.70 (mm, 1H), 2.57 (m, 1H), 2.38 (m, 1H), 2.12 (m, 1H),1.66 (tt, J= 7.4, 5.4 Hz, 2H), 1.61 – 1.52 (m, 2H), 1.38 – 1.26 (m, 8H).HRMS(ESI): m / z, calcd for C 44 H 44 N8NaO8S [M + Na] + , 867.2895; found, 867.2892.
[0066] Example 7: Synthesis of N-(5-((4-((2-(2-(2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)carbamoyl)benzyl)oxy)-1,3,4-thiadiazol-2-yl)-3-(2-methoxyphenyl)isonicotinamide (12f)
[0067] Structural formula:
[0068] Referring to the synthesis method of Example 2, the linker was replaced with 2,2'-(ethane-1,2-diylbis(oxy))bis(ethane-1-amine) (11f) of equal molar mass, and other conditions remained unchanged. 1 H NMR (400 MHz, CDCl 3 ) δ 8.75 (d, J =5.0 Hz, 1H), 8.68 (s, 1H), 7.83 (d, J = 8.0 Hz, 2H), 7.61 (d, J = 5.0 Hz, 1H),7.47 (dd, J = 8.5, 7.1 Hz, 1H), 7.42 – 7.32 (m, 3H), 7.24 (d, J = 1.8 Hz, 1H),7.10 – 6.99 (m, 2H), 6.86 (dd, J = 10.3, 8.5 Hz, 2H), 6.57 (t, J = 5.3 Hz, 1H),5.27 (s, 2H), 4.62 – 4.50 (m, 1H), 3.72 (d, J = 19.5 Hz, 9H), 3.59 (s, 4H), 3.43 (qd, J = 5.2, 2.9 Hz, 2H), 2.82 – 2.56 (m, 2H), 2.45 (td, J= 13.3, 7.2 Hz,1H), 2.00 – 1.90 (m, 1H).HRMS (ESI): m / z, calcd for C 42 H 40 N8NaO 10 S [M + Na] + ,871.2480; found, 871.2476.
[0069] Example 8: Synthesis of N-(5-((4-((10-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)decyl)carbamoyl)benzyl)oxy)-1,3,4-thiadiazol-2-yl)-3-(2-methoxyphenyl)isonicotinamide (12 g)
[0070] Structural formula:
[0071] Referring to the synthesis method of Example 2, the linker was replaced with decane-1,10-diamine (11 g) of equal molar mass, and other conditions remained unchanged. 1 H NMR (300 MHz, CDCl3) δ 8.79 (s, 1H), 8.69 (d, J = 5.0 Hz, 1H),8.61 (s, 1H), 7.79 – 7.70 (m, 2H), 7.61 (d, J = 5.0 Hz, 1H), 7.50 – 7.41 (m,3H), 7.38 (dd, J = 7.9, 1.8 Hz, 1H), 7.23 (dd, J = 7.5, 1.7 Hz, 1H), 7.06 (dd, J =7.2, 1.8 Hz, 2H), 6.89 (dd, J = 11.0, 8.4 Hz, 2H), 6.38 (t, J = 5.7 Hz, 1H), 6.21(t, J = 5.5 Hz, 1H), 5.42 (s, 2H), 4.89 (dd, J = 11.9, 5.4 Hz, 1H), 3.63 (s, 3H), 3.43 (q, J = 6.7 Hz, 2H), 3.25 (q, J= 6.6 Hz, 2H), 2.79 (m, 3H), 2.10 (dt, J =9.4, 3.1 Hz, 1H), 1.62 (dt, J = 13.6, 7.0 Hz, 4H), 1.30 (t, J = 6.4 Hz, 12H).HRMS(ESI): m / z, calcd for C 46 H 48 N8NaO8S [M + Na] + , 895.3208; found, 895.3203.
[0072] Example 9: Synthesis of N-(5-((4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperazin-1-yl)piperidine-1-carbonyl)benzyl)oxy)-1,3,4-thiadiazol-2-yl)-3-(2-methoxyphenyl)isonicotinamide (12h)
[0073] Structural formula:
[0074] Referring to the synthesis method of Example 2, the linker was replaced with 1-(piperidin-4-yl)piperazine (11h) of equal molar mass, and other conditions remained unchanged. 1 H NMR (300 MHz, CDCl3) δ 9.80 (s, 1H), 8.87 (d, J = 1.5 Hz, 1H),8.66 (dd, J = 4.6, 1.6 Hz, 1H), 7.86 – 7.81 (m, 2H), 7.66 – 7.60 (m, 2H), 7.55(dd, J = 7.7, 1.3 Hz, 1H), 7.51 (t, J = 7.3 Hz, 1H), 7.48 (q, J = 1.1 Hz, 1H), 7.46(t, J = 1.1 Hz, 1H), 7.33 (td, J = 7.6, 1.3 Hz, 1H), 7.24 – 7.19 (m, 2H), 7.02(dd, J = 7.7, 1.2 Hz, 1H), 5.49 (t, J = 3.6 Hz, 1H), 5.36 (t, J= 1.0 Hz, 2H), 3.67(s, 3H), 3.78 (ddd, J = 12.3, 7.6, 5.7 Hz, 2H), 3.47 (ddd, J = 12.3, 7.6, 5.8 Hz,2H), 3.36 – 3.13 (m, 4H), 2.73 (dd, J = 5.8, 4.1 Hz, 2H), 2.68 – 2.50 (m, 4H), 2.43 (p, J = 5.5 Hz, 1H), 2.21 (dddd, J = 12.5, 7.0, 4.5, 3.7 Hz, 1H), 1.77(dddd, J = 12.5, 7.0, 4.5, 3.7 Hz, 1H), 1.73 – 1.57 (m, 4H).HRMS (ESI): m / z,calcd for C 45 H 43 N9NaO8S [M + Na] + , 892.2848; found, 892.2842.
[0075] Example 10: Synthesis of N-(5-((4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperazin-1-yl)methyl)piperidine-1-carbonyl)benzyl)oxy)-1,3,4-thiadiazol-2-yl)-3-(2-methoxyphenyl)isonicotinamide (12i)
[0076] Structural formula:
[0077] Referring to the synthesis method of Example 2, the linker was replaced with 1-(piperidin-4-ylmethyl)piperazine (11i) of equal molar mass, and other conditions remained unchanged. 1H NMR (300 MHz, CDCl3) δ 8.74 – 8.68 (m, 2H), 7.95 (dd, J= 7.2, 1.2 Hz, 1H), 7.83 (d, J = 4.5 Hz, 1H), 7.72 – 7.66 (m, 2H), 7.64 (dd,J = 7.7, 1.3 Hz, 1H), 7.55 – 7.50 (m, 1H), 7.46 – 7.41 (m, 2H), 7.37 – 7.33(m, 1H), 7.32 – 7.25 (m, 1H), 6.99 (ddd, J = 11.8, 7.5, 1.3 Hz, 2H), 5.31 –5.43 (m, 2H), 4.95 – 4.78 (m, 1H), 3.65 (s, 3H), 3.74 (ddd, J = 12.0, 8.5,6.1 Hz, 2H), 3.71 – 3.59 (m, 2H), 3.41 – 3.32 (m, 4H), 2.76 – 2.65 (m, 5H), 2.57 (ddd, J = 14.8, 7.0, 4.3 Hz, 1H), 2.49 (d, J = 4.7 Hz, 2H), 2.38 (dddd,J = 13.2, 7.0, 4.3, 3.6 Hz, 1H), 2.12 (dddd, J = 13.2, 7.0, 4.4, 3.7 Hz, 1H),2.02 – 1.88 (m, 2H), 1.78 – 1.63 (m, 3H).HRMS (ESI): m / z, calcd forC 46 H 45 N9NaO8S [M + Na] + , 906.3004; found, 906.2999.
[0078] Example 11: Synthesis of N-(5-((4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)azetidine-1-carbonyl)benzyl)oxy)-1,3,4-thiadiazol-2-yl)-3-(2-methoxyphenyl)isonicotinamide (12j)
[0079] Structural formula:
[0080] Referring to the synthesis method of Example 2, the linker was replaced with 1-(azetidin-3-yl)piperazine (11j) of equal molar mass, and 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (D1) was replaced with 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (D2) of equal molar mass, and other conditions remained unchanged. 1 H NMR (300 MHz, CDCl3) δ 8.72 (d, J = 1.4 Hz, 1H), 8.70 (dd, J = 4.6, 1.5 Hz, 1H), 7.87 –7.82 (m, 2H), 7.70 – 7.66 (m, 2H), 7.64 (dd, J = 7.7, 1.4 Hz, 1H), 7.45 –7.41 (m, 2H), 7.38 – 7.33 (m, 2H), 7.28 (td, J = 7.5, 1.3 Hz, 1H), 6.96 (ddd,J = 17.3, 7.4, 1.7 Hz, 2H), 5.48 – 5.37 (m, 2H), 4.91 – 4.81 (m, 1H), 3.97(dd, J = 9.5, 4.0 Hz, 2H), 3.62 (s, 3H), 3.72 (dd, J = 9.5, 4.0 Hz, 2H), 3.44(p, J = 4.0 Hz, 1H), 3.33 – 3.28 (m, 4H), 2.85 – 2.80 (m, 4H), 2.70 (ddd, J =14.8, 7.0, 4.4 Hz, 1H), 2.57 (m, 1H), 2.40 (m, 1H), 2.14 (m, 1H).HRMS (ESI):m / z, calcd for C 43 H 39 N9NaO8S [M + Na] + , 864.2534; found, 864.2521.
[0081] Example 12: Synthesis of N-(5-((4-(9-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-3,9-diazaspiro[5.5]undecane-3-carbonyl)benzyl)oxy)-1,3,4-thiadiazol-2-yl)-3-(2-methoxyphenyl)isonicotinamide (12k)
[0082] Structural formula:
[0083] Referring to the synthesis method of Example 2, the linker was replaced with 3,9-diazaspiro[5.5]undecane (11k) of equal molar mass, and 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (D1) was replaced with 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (D2) of equal molar mass, and other conditions remained unchanged. 1 H NMR (300 MHz, Chloroform-d) δ 8.72 (d, J = 1.4 Hz, 1H), 8.70 (dd, J = 4.6, 1.5 Hz, 1H), 7.87 – 7.82 (m, 2H), 7.71 – 7.67 (m, 2H), 7.64 (dd, J = 7.6, 1.3 Hz, 1H), 7.45 – 7.41 (m, 2H), 7.38 – 7.33 (m, 2H), 7.28 (td, J = 7.5, 1.3 Hz, 1H), 6.98 (dd, J = 7.6, 1.2 Hz, 1H), 6.95 (dd, J = 7.2, 2.1 Hz, 1H), 5.44 – 5.35(m, 2H), 4.90 – 4.78 (m, 1H), 3.64 (s, 3H), 3.54 – 3.49 (m, 4H), 3.41 – 3.36(m, 4H), 2.63 (m, 2H), 2.40 (dddd, J = 13.2, 7.0, 4.3, 3.6 Hz, 1H), 2.14 (m,1H), 1.82 – 1.76 (m, 4H), 1.74 – 1.65 (m, 4H).HRMS (ESI): m / z, calcd forC 45 H 43 N8O8S [M + H] + , 855.2919; found, 855.2902.
[0084] Example 13: Activity Test
[0085] (I) ADP-GloTM luminescence assay to determine Polθ inhibitory activity in vitro
[0086] Experimental Materials
[0087] ADP-Glo™ kinase assay kit (Promega); ssDNA (Genscript); POLQ protein (In house); neomycin (MCE); 96-well plate (Nunc); 384-well plate (PE); centrifuge (Cence); microplate reader (BMG).
[0088] Test Method
[0089] Add 50 µL of compound to the 384-well dilution plate, dilute the compound 1:3 with DMSO per column (DMSO: compound = 1:3, v / v), and dilute 10 points serially. Use the Echo 650 sonic pipetting system to transfer 0.1 µL of the diluted compound solution per row to the 384-well assay plate, with 2 replicates for each compound. Add 5 µL of enzyme working solution (AiSiYiPu Technology Co., Ltd., S2201T-H02H) to the 384-well plate, centrifuge at 1000 rpm for 1 min, and incubate at 25°C for 10 min. Add 5 µL of working solution containing ssDNA (final concentration: 50 nM) and ATP (final concentration: 50 μM), centrifuge at 1000 rpm for 1 min, and incubate at 25°C for 60 min. Add 5 µL of ADP-Glo™ reagent, centrifuge at 1000 rpm for 1 min, and incubate at 25°C for 40 min. Add 10 µL of ADP-Glo™ Kinase Assay Solution and centrifuge at 1000 rpm for 1 minute.
[0090] Experimental data processing: Enzyme inhibition activity (%) = 100*(ave High control - cpd well) / (ave High control - ave Low control). The IC values of the compounds were fitted from the nonlinear regression equation using GraphPad Prism 8.4.3 software. 50 value.
[0091] Experimental results:
[0092] The specific results are shown in Table 1. 50 <100 nM (denoted as: A); IC 50 = 100 - 500nM (denoted as: B); IC 50 >500nM (denoted as: C).
[0093] Table 1 Inhibitory activity of compounds on Polθ
[0094]
[0095] (II) Western blot analysis of the effects of compounds on Polθ expression in MDA-MB-436 cells
[0096] Experimental methods:
[0097] MDA-MB-436 cells (Guangzhou Saiku Biotechnology Co., Ltd.) were treated with compound 12f (concentrations of 0.2, 2, and 20 μM, respectively) for 24 h, then the culture medium was discarded, washed 3 times with PBS, and 60 μL of a mixed solution of protease inhibitors and RIPA lysis buffer (the volume ratio of protease inhibitors to RIPA lysis buffer was 1:100) was added to completely lyse the cells, and then centrifuged (4°C, 12,000g, 10 min). The upper layer was the total protein solution obtained. GAPDH was used as an internal reference. According to the instructions of the 7.5% ExpressCast PAGE Color Gel Rapid Kit (Suzhou Xinsaimei Biotechnology Co., Ltd., P2011), separation gel and stacking gel were prepared according to the different molecular weights of the proteins to be tested, and SDS-PAGE gel was cast. After adding an appropriate amount of pre-cooled 1× electrophoresis buffer, the total protein extract in the cells was added to the lane (pre-stained protein Maker and sample). Electrophoresis was performed at 90V for about 30 minutes. After the sample entered the separation gel, the voltage was adjusted to 120V and continued electrophoresis. When the target band reached the appropriate position (refer to the position of the prestained protein Maker, the minimum molecular weight of the Marker ran to the bottom of the concentrated gel), the electrophoresis was terminated. Electrophoresis was terminated when bromophenol blue just ran out, and the mold was transferred. The band of the target protein was stripped out, attached to the PVDF membrane, transferred to the PVDF membrane by electrophoresis, and then blocked with 5% skim milk on a decolorizing shaker for 1 hour. Monoclonal anti-POLQ mouse antibody (Sigma-Aldrich, SAB1402530) was added, incubated at 4°C overnight, and then washed three times with TBST, each washing time was 10 minutes. HRP-coupled affinity goat anti-mouse IgG (H+L) (Proteintech, SA00001-1) was added, incubated at room temperature for 2 hours, and then washed three times with TBST, each washing time was 10 minutes. Prepare an ECL mixed solution in a dark room in advance by mixing ECLA and ECLB in a high-sensitivity ECL chemiluminescence kit (Suzhou Xinsaimei Biotechnology Co., Ltd., P2200) at a volume ratio of 1:1. Then place the treated PVDF membrane face up in an exposure box, add the prepared ECL mixed solution, react for 1-2 minutes, then discard the reaction solution, adjust the exposure conditions according to the luminescence intensity of the developing reagent, and start exposure.
[0098] Experimental results:
[0099] like Figure 1As shown, the compound 12f disclosed in the present invention exhibited a certain degree of degradation effect on Polθ relative to the control group; when the administration concentration was 0.2 µM, a certain degradation effect was exhibited 24 hours after administration; when the administration concentration was 2 µM, the degradation effect of compound 12f on Polθ was most obvious 24 hours after administration; at a dosage concentration of 20 µM, a HOOK effect occurred and protein expression increased.
Claims
1. A compound targeting degradation of Polθ or a pharmaceutically acceptable salt thereof, characterized in that: The structural formula of the compound targeting the degradation of Polθ is shown in any one of the following: 。 2. Use of the compound targeted for degradation of Polθ or a pharmaceutically acceptable salt thereof according to claim 1 in the preparation of a drug targeted for degradation of Polθ.
3. Use of the compound targeting degradation of Polθ or a pharmaceutically acceptable salt thereof according to claim 1 in the preparation of a drug for treating and / or preventing cancer.
Citation Information
Patent Citations
Thiadiazolyl derivatives as DNA polymerase Theta inhibitors
CN114127062A
O-linked thiadiazolyl compounds as DNA polymerase theta inhibitors
CN117794927A
Thiadiazole derivative and composition and application thereof
CN118055930A
Compound targeting polθ and use thereof
WO2024149349A1
